Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is poised for continued success with the recent announcement that KOMZIFTI, their once-daily, oral menin inhibitor, has seen initial sales and net product revenue of $2.1 million. This strong cash balance of approximately $667 million at YE25 positions the company well to execute on ongoing clinical and commercial objectives, with key milestones and catalysts expected in 2026 including the expansion of ziftomenib to non-AML indications, the presentation of updated KOMET-007 data, and the initiation of a Phase 1a dose escalation trial evaluating combination with imatinib in gastrointestinal stromal tumors.

Kura Oncology is facing several potential challenges with its lead candidate ziftomenib, which is being evaluated in combination with various backbones in its KOMET-017 Phase 3 program. While the 100% CR rate in elderly patients and median CR duration yet to be reached are encouraging signs, the Phase 1a data for KOMET-007 might be skewed towards higher-risk, younger patients and therefore not fully reflective of the broader 1L population. Additionally, the company's expected expansion into the larger 1L and combination settings may depend on the success of its ongoing Phase 3 program.